Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment

Japanese Journal of Nephrology

Volumn 38, Issue 1, 1996, Pages 46-51

  Okada, Tomonari ^a   Takahashi, Hajime ^a   Ogura, Makoto ^a   Nakao, Toshiyuki ^a   Shimizu, Tohru ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

cyclosporin; hyperlipidemia; low density lipoprotein apheresis; minimal change nephrotic; steroid resistant nephrotic syndrome; syndrome

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE;

ADULT; APHERESIS; ARTICLE; CASE REPORT; HUMAN; HYPERLIPIDEMIA; MALE; NEPHROTIC SYNDROME;

ADULT; ANTI-INFLAMMATORY AGENTS; BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; CYCLOSPORINE; DRUG RESISTANCE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS, LDL; MALE; NEPHROSIS, LIPOID; PREDNISOLONE; REMISSION INDUCTION;

EID: 0029965296     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ponticelli C, Passerin P: Treatment of the nephrotic syndrome associated with primary glomerulonephritis. Kidney Int 46: 595-604, 1994
2. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Casa-Alberighi OD: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43: 1377-1384, 1993
3. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S: Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9: 257-264, 1994
4. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams G: Adult-onset minimal change nephrotic syndrome: A long-term follow-up. Kidney Int 29: 1215-1223, 1986
5. Korbet SM, Schwartz MM, Lewis EJ: Minimal-change glomerulopathy of adulthood. Am J Nephrol 8: 291-297, 1988
6. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K: Minimal change nephrotic syndrome in adults: Response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis: 17 687-692, 1991
7. Schnaper HW, Robson AM: Nephrotic syndrome minimal change disease, focal glomerulosclerosis, and related disorders. Diseases of the kidney; ed by Schrier RW, Gottschalk CW, Little, Brown and company, Boston, pp1731-1784, 1993
8. Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell Jr RC, Ichikawa I: Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 38: 115-123, 1990
9. Nadasdy T, Silva FG, Hogg RJ: Minimal change nephrotic syndrome-focal sclerosis complex (including IgM nephropathy and diffuse mesangial hypercellularity). Renal Pathology With Clinical and Functional Correlations; ed by Tisher CC, Brenner BM, J. B. Lippincott Company, Philadelphia, pp330-389, 1994
10. Hoyer PF, Brodehl J, Ehrich JHH, Offner G: Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 5: 630-638, 1991
11. Faulds D, Goa KL, Benfield P: Cyclosporin, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040, 1993
12. Kivisto KT: A review of assay methods for Cyclosporin, clinical implications. Clin Pharmacokinet 23: 173-190, 1992
13. Grevel J: Optimisation of immunosuppressive therapy using phamacokinetic principles. Clin Pharmacokinet 23: 380-390, 1992
14. Collaborative study group of Sandimmun in nephrotic syndrome: Safety and tolerability of cyclosporin A in idiopathic nephrotic syndrome. Clin Nephrol 35: S. 48-60, 1991
15. Meyrier A, Noel LH, Auriche P, Callard P, and the collaborative group of the societe de nephrogie, with the technical assistance of Broneer D: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 45: 1446-1456, 1994
16. de Groen PC: Cyclosporine, Low-Density Lipoprotein, and Cholesterol. Mayo Clin Proc 63: 1012-1021, 1988
17. Sanghvi A, Warty V, Zeevi A, Diven W, Duquesnoy R, Makowka L, Starzl TE: FK506 enhances cyclosporine uptake by peripheral blood lymphocytes. Transplant Proc 19 (suppl 6): 45-49, 1987
18. de Groen PC, Wiesner RH, Krom RAF: Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay? Transplant Proc 20 (suppl 2): 374-376, 1988
19. Ingulli E, Tejani A, Butt KMH, Rajpoot D, Gonzalez R, Pomrantz A, Ettenger R: High-dose cyclosporine therapy in recurrent nephrotic syndrome following renal transplantation. Transplantation 49: 219-221, 1990
20. Nemunaitis J, Deeg HJ, Yee GC: High cyclosporine levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet; 2: 744-745, 1986
21. Ingulli E, Tejani A: Severe hypercholesterolemia inhibits cyclosporine A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephro 13: 254-259, 1992
22. Ingulli E, Singh A, Baqi N, Amad H, Moazami S, Tejani A: Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomeruloscle rosis. J Am Soc Nephrol 5: 1820-1825, 1995